A Prospective Cohort of Pulmonary Ground Glass Nodules Patients With Family History.
GGN-F
Clinical Database and Biobank of Pulmonary Ground Glass Nodules Patients With Family History, a Prospective Cohort Study.
1 other identifier
observational
600
1 country
1
Brief Summary
The aim of the present prospective cohort study (GGN-F) is to study the family aggregation of pulmonary ground glass nodules via the questionnaire survey and to investigate the underlying genetic mechanism via the biobank.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2020
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 5, 2020
CompletedStudy Start
First participant enrolled
January 5, 2020
CompletedFirst Posted
Study publicly available on registry
January 7, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 5, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
January 31, 2022
CompletedJanuary 7, 2020
January 1, 2020
2 years
January 5, 2020
January 5, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The prevalence of family aggregation of pulmonary ground glass nodule.
To investigate the aggregation of pulmonary ground glass nodule among first-degree relatives of participants via the questionnaire.
1 week
Secondary Outcomes (1)
Susceptibility genetic events related to the family aggregation of ground glass nodules.
1 month
Study Arms (1)
Participants
All the patients with proved malignant ground glass nodule will be enrolled.
Eligibility Criteria
All the patients with pulmonary ground glass nodules and pathological proved malignant disease will be enrolled.
You may qualify if:
- patients with informed consent;
- patients with pulmonary ground glass nodule.
- pathological proved early stage lung cancer.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China
Related Publications (1)
Dai J, Lv J, Zhu M, Wang Y, Qin N, Ma H, He YQ, Zhang R, Tan W, Fan J, Wang T, Zheng H, Sun Q, Wang L, Huang M, Ge Z, Yu C, Guo Y, Wang TM, Wang J, Xu L, Wu W, Chen L, Bian Z, Walters R, Millwood IY, Li XZ, Wang X, Hung RJ, Christiani DC, Chen H, Wang M, Wang C, Jiang Y, Chen K, Chen Z, Jin G, Wu T, Lin D, Hu Z, Amos CI, Wu C, Wei Q, Jia WH, Li L, Shen H. Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. Lancet Respir Med. 2019 Oct;7(10):881-891. doi: 10.1016/S2213-2600(19)30144-4. Epub 2019 Jul 17.
PMID: 31326317BACKGROUND
Biospecimen
Blood and surgical tumor samples of all the participants will be collected. Moreover, blood samples of other family members of participants will be collected, with their consent and knowledge.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Wenzhao Zhong, Ph。D
Guangdong Provincial People's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Porfessor
Study Record Dates
First Submitted
January 5, 2020
First Posted
January 7, 2020
Study Start
January 5, 2020
Primary Completion
January 5, 2022
Study Completion
January 31, 2022
Last Updated
January 7, 2020
Record last verified: 2020-01
Data Sharing
- IPD Sharing
- Will not share